Tekla Capital Management as of Sept. 30, 2013
Portfolio Holdings for Tekla Capital Management
Tekla Capital Management holds 63 positions in its portfolio as reported in the September 2013 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Gilead Sciences (GILD) | 10.5 | $95M | 1.5M | 62.84 | |
| Regeneron Pharmaceuticals (REGN) | 9.1 | $82M | 261k | 312.87 | |
| Celgene Corporation | 8.7 | $79M | 510k | 153.93 | |
| Biogen Idec (BIIB) | 5.1 | $46M | 192k | 240.76 | |
| Amgen (AMGN) | 5.1 | $46M | 412k | 111.94 | |
| Alexion Pharmaceuticals | 4.8 | $43M | 371k | 116.16 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 4.2 | $38M | 500k | 75.82 | |
| Perrigo Company | 2.8 | $25M | 203k | 123.38 | |
| Puma Biotechnology (PBYI) | 2.7 | $25M | 459k | 53.66 | |
| Mylan | 2.1 | $19M | 488k | 38.17 | |
| Shire | 2.1 | $19M | 154k | 119.89 | |
| Akorn | 2.0 | $18M | 936k | 19.68 | |
| iShares NASDAQ Biotechnology Index (IBB) | 2.0 | $18M | 84k | 209.60 | |
| Warner Chilcott Plc - | 1.8 | $16M | 714k | 22.85 | |
| Incyte Corporation (INCY) | 1.8 | $16M | 421k | 38.15 | |
| Aetna | 1.8 | $16M | 247k | 64.02 | |
| Onyx Pharmaceuticals | 1.7 | $16M | 124k | 124.67 | |
| Allergan | 1.7 | $15M | 167k | 90.45 | |
| Cubist Pharmaceuticals | 1.6 | $14M | 227k | 63.55 | |
| Merck & Co (MRK) | 1.6 | $14M | 297k | 47.61 | |
| Teva Pharmaceutical Industries (TEVA) | 1.5 | $13M | 355k | 37.78 | |
| Actavis | 1.5 | $13M | 92k | 144.00 | |
| BioMarin Pharmaceutical (BMRN) | 1.5 | $13M | 182k | 72.22 | |
| Hologic (HOLX) | 1.4 | $12M | 593k | 20.65 | |
| Alere | 1.3 | $11M | 370k | 30.57 | |
| Verastem | 1.2 | $11M | 885k | 12.44 | |
| Questcor Pharmaceuticals | 1.1 | $9.4M | 162k | 58.00 | |
| Ironwood Pharmaceuticals (IRWD) | 1.0 | $9.1M | 768k | 11.85 | |
| Amarin Corporation (AMRN) | 1.0 | $8.8M | 1.4M | 6.32 | |
| Illumina (ILMN) | 0.9 | $8.4M | 104k | 80.83 | |
| Ariad Pharmaceuticals | 0.8 | $7.6M | 413k | 18.40 | |
| McKesson Corporation (MCK) | 0.8 | $7.3M | 57k | 128.29 | |
| Impax Laboratories | 0.8 | $7.1M | 345k | 20.51 | |
| Alkermes (ALKS) | 0.7 | $6.6M | 195k | 33.62 | |
| Neurocrine Biosciences (NBIX) | 0.7 | $6.5M | 570k | 11.32 | |
| Forest Laboratories | 0.7 | $6.3M | 147k | 42.79 | |
| Infinity Pharmaceuticals (INFIQ) | 0.7 | $6.1M | 350k | 17.45 | |
| UnitedHealth (UNH) | 0.7 | $5.9M | 82k | 71.61 | |
| Endo Pharmaceuticals | 0.6 | $5.7M | 126k | 45.44 | |
| IDEXX Laboratories (IDXX) | 0.6 | $5.6M | 56k | 99.65 | |
| Medivation | 0.6 | $5.5M | 92k | 59.93 | |
| Sagent Pharmaceuticals | 0.6 | $5.5M | 270k | 20.40 | |
| Accuray Incorporated (ARAY) | 0.6 | $5.4M | 732k | 7.39 | |
| Baxter International (BAX) | 0.6 | $5.1M | 78k | 65.68 | |
| Auxilium Pharmaceuticals | 0.5 | $4.6M | 250k | 18.23 | |
| AVANIR Pharmaceuticals | 0.5 | $4.1M | 960k | 4.24 | |
| Acorda Therapeutics | 0.4 | $3.9M | 113k | 34.28 | |
| Merrimack Pharmaceuticals In | 0.4 | $3.8M | 1.0M | 3.80 | |
| Elan Corporation | 0.4 | $3.8M | 243k | 15.58 | |
| Intellipharmaceuticsintl Inc C | 0.4 | $3.4M | 1.7M | 1.96 | |
| CVS Caremark Corporation (CVS) | 0.3 | $3.0M | 54k | 56.75 | |
| Synta Pharmaceuticals | 0.3 | $3.1M | 490k | 6.31 | |
| Mei Pharma | 0.3 | $2.8M | 244k | 11.34 | |
| NPS Pharmaceuticals | 0.2 | $1.9M | 61k | 31.81 | |
| Gentium S.p.A. | 0.2 | $1.8M | 65k | 27.13 | |
| Raptor Pharmaceutical | 0.2 | $1.6M | 110k | 14.94 | |
| Alnylam Pharmaceuticals (ALNY) | 0.2 | $1.5M | 24k | 64.01 | |
| Clovis Oncology | 0.1 | $1.4M | 23k | 60.78 | |
| OncoGenex Pharmaceuticals | 0.1 | $1.0M | 113k | 9.27 | |
| Aegerion Pharmaceuticals | 0.1 | $1.0M | 12k | 85.69 | |
| Supernus Pharmaceuticals (SUPN) | 0.1 | $1.0M | 141k | 7.33 | |
| Ceres | 0.1 | $426k | 286k | 1.49 | |
| Icad (ICAD) | 0.1 | $467k | 89k | 5.28 |
